The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...
Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...
Fintel reports that on April 2, 2025, Lake Street initiated coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 865.16% Upside As of March 19, 2025, the ...
Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
Compass Therapeutics (NASDAQ:CMPX) stock gains as its oncology drug tovecimig hits main goal in a Phase 2/3 trial for biliary ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
MyChesCo on MSN3d
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
The Apple Watch offers plenty of health features, but Apple is apparently stepping things up with an AI doctor of sorts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback